Endocrine resistance in breast cancer - An overview and update

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 220-234

  Clarke, Robert ^a   Tyson, John J ^b   Dixon, J Michael ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Antiestrogens; Autophagy; Breast cancer; Computational biology; Endocrine resistance; Systems biology; Tamoxifen; Unfolded protein response

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ARN 810; AROMATASE INHIBITOR; COREGULATOR PROTEIN; CYTOCHROME P450 2D6 INHIBITOR; ESTROGEN RECEPTOR ALPHA; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GDC 810; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MPDL 3280A; PALBOCICLIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; REGULATOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STERYL SULFATASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; TRASTUZUMAB; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER RISK; CELL CYCLE PROGRESSION; CELL HETEROGENEITY; CELL METABOLISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCRINE RESISTANCE; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ERALPHA GENE; GENE FUNCTION; GENE MUTATION; HUMAN; METASTASIS; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; OVARY FUNCTION; OVERALL SURVIVAL; PHARMACODYNAMICS; PHARMACOGENETICS; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; UNFOLDED PROTEIN RESPONSE; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENETICS; MUTATION;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MUTATION; UNFOLDED PROTEIN RESPONSE;

EID: 84949564106     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.09.035     Document Type: Article

References (206)

1. Aihara T., Yokota I., Hozumi Y., Aogi K., Iwata H., Tamura M., Fukuuchi A., Makino H., Kim R., Andoh M., Tsugawa K., Ohno S., Yamaguchi T., Ohashi Y., Watanabe T., Takatsuka Y., Mukai H. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial. Breast Cancer Res. Treat. 2014, 148:337-343.
2. Al-Mubarak M., Sacher A.G., Ocana A., Vera-Badillo F., Seruga B., Amir E. Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treat. Rev. 2013, 39:753-758.
3. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
4. Allred D.C., Harvey J.M., Berardo M., Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11:155-168.
5. Almog N., Ma L., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J., Abdollahi A. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009, 69:836-844.
6. Anbalagan M., Rowan B.G. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol. Cell Endocrinol. 2015, pii: S0303-7207(15)00020-9, [Epub ahead of print]. 10.1016/j.mce.2015.01.016.
7. Andre F., Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res. Treat. 2015, 150:1-8.
8. Andres S.A., Wittliff J.L. Relationships of ESR1 and XBP1 expression in human breast carcinoma and stromal cells isolated by laser capture microdissection compared to intact breast cancer tissue. Endocrine 2011, 40:212-221.
9. Andruska N., Zheng X., Yang X., Helferich W.G., Shapiro D.J. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor alpha-positive breast cancer. Oncogene 2015, 34:3760-3769.
10. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
11. Ariazi E.A., Cunliffe H.E., Lewis-Wambi J.S., Slifker M.J., Willis A.L., Ramos P., Tapia C., Kim H.R., Yerrum S., Sharma C.G., Nicolas E., Balagurunathan Y., Ross E.A., Jordan V.C. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18879-18886.
12. Babayan A., Hannemann J., Spotter J., Muller V., Pantel K., Joosse S.A. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 2013, 8:e75038.
13. Barone I., Brusco L., Fuqua S.A. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin. Cancer Res. 2010, 16:2702-2708.
14. Barton V.N., D'Amato N.C., Gordon M.A., Christenson J.L., Elias A., Richer J.K. Androgen receptor biology in triple negative breast Cancer: a case for classification as AR+ or quadruple negative disease. Horm. Cancer 2015.
15. Barton V.N., D'Amato N.C., Gordon M.A., Lind H.T., Spoelstra N.S., Babbs B.L., Heinz R.E., Elias A., Jedlicka P., Jacobsen B.M., Richer J.K. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol. Cancer Ther. 2015, 14:769-778.
16. Bartsch R., Bago-Horvath Z., Berghoff A., DeVries C., Pluschnig U., Dubsky P., Rudas M., Mader R.M., Rottenfusser A., Fitzal F., Gnant M., Zielinski C.C., Steger G.G. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur. J. Cancer 2012, 48:1932-1938.
17. Beckwith H., Yee D. Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy. Endocr. Pract. 2014, 20:1214-1221.
18. Berry J., Green B.J., Matheson D.S. Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminogluthemide. Cancer Immunol. Immunother. 1987, 24:72-75.
19. Berry J., Green B.J., Matheson D.S. Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer. Eur. J. Cancer Clin. Oncol. 1987, 23:517-520.
20. Blackburn H.L., Ellsworth D.L., Shriver C.D., Ellsworth R.E. Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control 2015, 26:319-332.
21. Booth L., Cazanave S.C., Hamed H.A., Yacoub A., Ogretmen B., Chen C.S., Grant S., Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol. Ther. 2012, 13:224-236.
22. Booth L., Roberts J.L., Cash D.R., Tavallai S., Jean S., Fidanza A., Cruz-Luna T., Siembiba P., Cycon K.A., Cornelissen C.N., Dent P. GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. J. Cell Physiol. 2015, 230:1661-1676.
23. Brouckaert O., Paridaens R., Floris G., Rakha E., Osborne K., Neven P. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann. Oncol. 2013, 24:47-53.
24. Burstein H.J., Temin S., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E., Giordano S.H., Hudis C.A., Rowden D., Solky A.J., Stearns V., Winer E.P., Griggs J.J. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J. Clin. Oncol. 2014, 32:2255-2269.
25. Burstein H.J., Cirrincione C.T., Barry W.T., Chew H.K., Tolaney S.M., Lake D.E., Ma C., Blackwell K.L., Winer E.P., Hudis C.A. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J. Clin. Oncol. 2014, 32:3959-3966.
26. Cameron D.A., Keen J.C., Dixon J.M., Bellamy C., Hanby A., Anderson T.J., Miller W.R. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur. J. Cancer 2000, 36:845-851.
27. Carlson R.W., Henderson I.C. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res. Treat. 2003, 80(Suppl. 1):S19-S26.
28. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest 2008, 118:3065-3074.
29. Chakrabarty A., Sanchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2718-2723.
30. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
31. Chen C., Baumann W.T., Clarke R., Tyson J.J. Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. FEBS Lett. 2013, 587:3327-3334.
32. Chen C., Baumann W.T., Xing J., Xu L., Clarke R., Tyson J.J. Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. J. R. Soc. Interface 2014, 11:20140206.
33. Chien C.D., Kirilyuk A., Li J.V., Zhang W., Lahusen T., Schmidt M.O., Oh A.S., Wellstein A., Riegel A.T. Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription. J. Biol. Chem. 2011, 286:26813-26827.
34. Ciruelos Gil E. M. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 2014, 40:862-871.
35. Clarke R., Brünner N. Cross resistance and molecular mechanisms in antiestrogen resistance. Endocr. Relat. Cancer 1995, 2:59-72.
36. Clarke R., van den Berg H.W., Kennedy D.G., Murphy R.F. Reduction of the antimetabolic and antiproliferative effects of methotrexate by 17β-estradiol in a human breast carcinoma cell line (MDA-MB-436). Eur. J. Cancer Clin. Oncol. 1983, 19:19-24.
37. Clarke R., Brünner N., Katz D., Glanz P., Dickson R.B., Lippman M.E., Kern F. The effects of a constitutive production of TGF-α on the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol. Endocrinol. 1989, 3:372-380.
38. Clarke R., Hilakivi-Clarke L.A., Cho E., James M.R., Leonessa F. Estrogens, phytoestrogens and breast cancer. Adv. Exp. Biol. Med. 1996, 401:63-86.
39. Clarke R., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 2001, 53:25-71.
40. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 2001, 76:71-84.
41. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
42. Clarke R., Ressom H.W., Wang A., Xuan J., Liu M.C., Gehan E.A., Wang Y. The properties of very high dimensional data spaces: implications for exploring gene and protein expression data. Nat. Rev. Cancer 2008, 8:37-49.
43. Clarke R., Shajahan A.N., Riggins R., Cho Y., Crawford A.C., Xuan J., Wang Y., Zwart A., Nehra N., Liu M.C. Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2009, 114:8-20.
44. Clarke R., Shajahan A.N., Wang Y., Tyson J.J., Riggins R., Weiner L.M., Baumann W.T., Xuan J., Zhang B., Facey C., Aiyer H., Cook K., Hickman F.E., Tavassoly I., Verdugo A., Chen C., Zwart A., Wärri A., Hilakivi-Clarke L.A. Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Horm. Mol. Biol. Clin. Invest 2011, 5:35-44.
45. Clarke R., Cook K.L., Hu R., Facey C.O., Tavassoly I., Schwartz J.L., Baumann W.T., Tyson J.J., Xuan J., Wang Y., Warri A., Shajahan A.N. Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res. 2012, 72:1321-1331.
46. Cole M.P., Jones C.T.A., Todd I.D.H. A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474. Br. J. Cancer 1971, 25:270-275.
47. Coller J.K., Krebsfaenger N., Klein K., Endrizzi K., Wolbold R., Lang T., Nussler A., Neuhaus P., Zanger U.M., Eichelbaum M., Murdter T.E. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br. J. Clin. Pharmacol. 2002, 54:157-167.
48. Cook K.L., Shajahan A.N., Jin L., Warri A., Hilakivi-Clarke L.A., Clarke R. Glucose-regulated protein 78 controls cross-talk between apoptotsis and autophagy to determine antiestrogen responsiveness. Cancer Res. 2012, 72:3337-3349.
49. Cook K.L., Wärri A., Soto-Pantoja D.R., Clarke P.A.G., Cruz M.I., Zwart A., Clarke R. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin. Cancer Res. 2014, 20:3222-3232.
50. Cook K.L., Clarke P.A.G., Parmar J., Hu R., Schwartz-Roberts J.L., Abu-Asab M., Wärri A., Baumann W.T., Clarke R. Knockdown of estrogen receptor alpha induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation promoting ROS-induced breast cancer cell death. FASEB J. 2014, 28:3891-3905.
51. Crawford A.C., Riggins R., Shajahan A.N., Zwart A., Clarke R. Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS One 2010, 5:e8604. 10.1371/journal.pone.0008604.
52. Creighton C.J., Fu X., Hennessy B.T., Casa A.J., Zhang Y., Gonzalez-Angulo A.M., Lluch A., Gray J.W., Brown P.H., Hilsenbeck S.G., Osborne C.K., Mills G.B., Lee A.V., Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010, 12:R40.
53. Crowder R.J., Phommaly C., Tao Y., Hoog J., Luo J., Perou C.M., Parker J.S., Miller M.A., Huntsman D.G., Lin L., Snider J., Davies S.R., Olson J.A., Watson M.A., Saporita A., Weber J.D., Ellis M.J. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009, 69:3955-3962.
54. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., Forbes J.F. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010, 11:1135-1141.
55. Dalvai M., Bystricky K. Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One 2010, 5:e11011.
56. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4037-4041.
57. Davies M.P., Barraclough D.L., Stewart C., Joyce K.A., Eccles R.M., Barraclough R., Rudland P.S., Sibson D.R. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int. J. Cancer 2008, 123:85-88.
58. Day J.M., Foster P.A., Tutill H.J., Parsons M.F., Newman S.P., Chander S.K., Allan G.M., Lawrence H.R., Vicker N., Potter B.V., Reed M.J., Purohit A. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int. J. Cancer 2008, 122:1931-1940.
59. De L.M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., Tortora G., D'Agostino D., Caputo F., Cancello G., Montagna E., Malorni L., Zinno L., Lauria R., Bianco A.R., De P.S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 2005, 11:4741-4748.
60. DeMichele A., Troxel A.B., Berlin J.A., Weber A.L., Bunin G.R., Turzo E., Schinnar R., Burgh D., Berlin M., Rubin S.C., Rebbeck T.R., Strom B.L. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J. Clin. Oncol. 2008, 26:4151-4159.
61. Demicheli R., Ardoino I., Boracchi P., Coradini D., Agresti R., Ferraris C., Gennaro M., Hrushesky W.J., Biganzoli E. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010, 10:656.
62. Di L.A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Garnett S., Lindemann J.P., Sapunar F., Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 2010, 28:4594-4600.
63. Dickson R.B., Lippman M.E. Growth factors in breast cancer. Endocr. Rev. 1995, 16:559-589.
64. Dickson R.B., McManaway M.E., Lippman M.E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986, 232:1540-1543.
65. Ding L.H., Ye Q.N., Zhu J.H., Yan J.H., Zhong H.J., Wang Z.H., Huang C.F. XBP-1 enhances the transcriptional activity of estrogen receptor alpha. Acta Biochim. BioIphys Sin. 2003, 35:829-833.
66. Ding L., Yan J., Zhu J., Zhong H., Lu Q., Wang Z., Huang C., Ye Q. Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res. 2003, 31:5266-5274.
67. Dong D., Ni M., Li J., Xiong S., Ye W., Virrey J.J., Mao C., Ye R., Wang M., Pen L., Dubeau L., Groshen S., Hofman F.M., Lee A.S. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008, 68:498-505.
68. Dong D., Stapleton C., Luo B., Xiong S., Ye W., Zhang Y., Jhaveri N., Zhu G., Ye R., Liu Z., Bruhn K.W., Craft N., Groshen S., Hofman F.M., Lee A.S. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res. 2011, 71:2848-2857.
69. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., Buyse M., Baum M., Buzdar A., Colleoni M., Coombes C., Snowdon C., Gnant M., Jakesz R., Kaufmann M., Boccardo F., Godwin J., Davies C., Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 2010, 28:509-518.
70. du M.S., Orsetti B., Bras-Goncalves R., Nguyen T.T., Lasorsa L., Boissiere F., Massemin B., Colombo P.E., Bibeau F., Jacot W., Theillet C. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol. Oncol. 2014, 8:431-443.
71. Early Breast Cancer Trialist's Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467.
72. Eirew P., Steif A., Khattra J., Ha G., Yap D., Farahani H., Gelmon K., Chia S., Mar C., Wan A., Laks E., Biele J., Shumansky K., Rosner J., McPherson A., Nielsen C., Roth A.J., Lefebvre C., Bashashati A., de S.C., Siu C., Aniba R., Brimhall J., Oloumi A., Osako T., Bruna A., Sandoval J.L., Algara T., Greenwood W., Leung K., Cheng H., Xue H., Wang Y., Lin D., Mungall A.J., Moore R., Zhao Y., Lorette J., Nguyen L., Huntsman D., Eaves C.J., Hansen C., Marra M.A., Caldas C., Shah S.P., Aparicio S. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015, 518:422-426.
73. Ellis P.A., Smith I.E., Detre S., Burton S.A., Salter J., A'Hern R., Walsh G., Johnston S.R., Dowsett M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res. Treat. 1998, 48:107-116.
74. Ellis M.J., Tao Y., Luo J., A'Hern R., Evans D.B., Bhatnagar A.S., Chaudri Ross H.A., von K.A., Miller W.R., Smith I., Eiermann W., Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl. Cancer Inst. 2008, 100:1380-1388.
75. Enderling H., Anderson A.R., Chaplain M.A., Beheshti A., Hlatky L., Hahnfeldt P. Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. Cancer Res. 2009, 69:8814-8821.
76. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Fowst C., Huang X., Kim S.T., Randolph S., Slamon D.J. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015, 16:25-35.
77. Forde P.M., Reiss K.A., Zeidan A.M., Brahmer J.R. What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013, 18:1203-1213.
78. Fu Y., Li J., Lee A.S. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007, 67:3734-3740.
79. Fuqua S.A., Gu G., Rechoum Y. Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res. Treat. 2014, 144:11-19.
80. Furr B.J.A., Jordan V.C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 1984, 25:127-205.
81. Garcia T., Lehrer S., Bloomer W.D., Schachter B. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol. Endocrinol. 1988, 2:785-791.
82. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., Patnaik A., Aggarwal C., Gubens M., Horn L., Carcereny E., Ahn M.J., Felip E., Lee J.S., Hellmann M.D., Hamid O., Goldman J.W., Soria J.C., Dolled-Filhart M., Rutledge R.Z., Zhang J., Lunceford J.K., Rangwala R., Lubiniecki G.M., Roach C., Emancipator K., Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:2018-2028.
83. Garreau J.R., Delamelena T., Walts D., Karamlou K., Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am. J. Surg. 2006, 192:496-498.
84. Gee J.M., Robertson J.F., Ellis I.O., Willsher P., McClelland R.A., Hoyle H.B., Kyme S.R., Finlay P., Blamey R.W., Nicholson R.I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer 1994, 59:619-628.
85. Goetz M.P., Ingle J.N. CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies. Clin. Pharmacol. Ther. 2014, 96:141-144.
86. Gomez B.P., Riggins R., Shajahan A.N., Klimach U., Wang A., Crawford A.C., Zhu Y., Zwart A., Wang M., Clarke R. Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J. 2007, 21:4013-4027.
87. Graham J.D., Bain D.L., Richer J.K., Jackson T.A., Tung L., Horwitz K.B. Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?. J. Steroid Biochem. Mol. Biol. 2000, 74:255-259.
88. Gu Z., Lee R.Y., Skaar T.C., Bouker K.B., Welch J.N., Lu J., Liu A., Zhu Y., Davis N., Leonessa F., Brunner N., Wang Y., Clarke R. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Res. 2002, 62:3428-3437.
89. Gusterson B. Do 'basal-like' breast cancers really exist?. Nat. Rev. Cancer 2009, 9:128-134.
90. Hershman D.L., Kushi L.H., Shao T., Buono D., Kershenbaum A., Tsai W.Y., Fehrenbacher L., Lin Gomez S., Miles S., Neugut A.I. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-etage breast cancer patients. J. Clin. Oncol. 2010, 28:4120-4128.
91. Higgins M.J., Rae J.M., Flockhart D.A., Hayes D.F., Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?. J. Natl. Compr. Canc Netw. 2009, 7:203-213.
92. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 1:149-153.
93. Hong W., Chen L., Li J., Yao Z. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells. Biochem. Biophys. Res. Commun. 2010, 396:299-303.
94. Howe L.R., Brown P.H. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev. Res. (Phila) 2011, 4:1149-1157.
95. Howell A., Robertson J.F., Quaresma A.J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20:3396-3403.
96. Hu R., Hilakivi-Clarke L., Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncol. Lett. 2015, 9:1495-1501.
97. Hu R., Warri A., Jin L., Zwart A., RIggins R.B., Clarke R. NFκB is required for XBP1 (U and S) mediated effects on antiestrogen responsiveness and cell fate decisions. Mol. Cell Biol. 2015, 35:379-390.
98. Huang Z., Fasco M.J., Figge H.L., Keyomarsi K., Kaminsky L.S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos. 1996, 24:899-905.
99. Huang P., Chandra V., Rastinejad F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol. 2010, 72:247-272.
100. Iacopino F., Robustelli della C.G., Sica G. Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines. Int. J. Cancer 1997, 71:1103-1108.
101. James M.R., Skaar T.C., Lee R.Y., MacPherson A., Zwiebel J.A., Ahluwalia B.S., Ampy F., Clarke R. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 2001, 142:1497-1505.
102. Jeselsohn R., Yelensky R., Buchwalter G., Frampton G., Meric-Bernstam F., Gonzalez-Angulo A.M., Ferrer-Lozano J., Perez-Fidalgo J.A., Cristofanilli M., Gomez H., Arteaga C.L., Giltnane J., Balko J.M., Cronin M.T., Jarosz M., Sun J., Hawryluk M., Lipson D., Otto G., Ross J.S., Dvir A., Soussan-Gutman L., Wolf I., Rubinek T., Gilmore L., Schnitt S., Come S.E., Pusztai L., Stephens P., Brown M., Miller V.A. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 2014, 20:1757-1767.
103. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., Skaar T.C. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004, 85:151-159.
104. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H.L., Romieu G., Manikhas A., Kennedy M.J., Press M.F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 2009, 27:5538-5546.
105. Jordan V.C., Robinson S.P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc. 1987, 46:1870-1874.
106. Ju Y.H., Doerge D.R., Allred K.F., Allred C.D., Helferich W.G. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002, 62:2474-2477.
107. Ju Y.H., Doerge D.R., Woodling K.A., Hartman J.A., Kwak J., Helferich W.G. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008, 29:2162-2168.
108. Karali E., Bellou S., Stellas D., Klinakis A., Murphy C., Fotsis T. VEGF Signals through ATF6 and PERK to promote endothelial cell survival and angiogenesis in the absence of ER stress. Mol. Cell 2014, 54:559-572.
109. Karnik P.S., Kulkarni S., Liu X.P., Budd G.T., Bukowski R.M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994, 54:349-353.
110. Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Revil C., Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 2009, 27:5529-5537.
111. Keeton E.K., Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol. Endocrinol. 2005, 19:1543-1554.
112. Kern F.G., McLeskey S.W., Zhang L., Kurebayashi J., Liu Y., Ding I., Kharbanda S., Chen D., Miller D., Cullen K., Paik S., Dickson R.B. Transfected MCF-7 cells as a model for breast cancer progression. Breast Cancer Res. Treat. 1994, 31:153-165.
113. Koeberle D., Ruhstaller T., Jost L., Pagani O., Zaman K., von M.R., Oehlschlegel C., Crowe S., Pilop C., Thuerlimann B. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr. Relat. Cancer 2011, 18:257-264.
114. Kohler B.A., Sherman R.L., Howlader N., Jemal A., Ryerson A.B., Henry K.A., Boscoe F.P., Cronin K.A., Lake A., Noone A.M., Henley S.J., Eheman C.R., Anderson R.N., Penberthy L. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J. Natl. Cancer Inst. 2015, 107.
115. Koumenis C., Wouters B.G. Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol. Cancer Res. 2006, 4:423-436.
116. Kuske B., Naughton C., Moore K., Macleod K.G., Miller W.R., Clarke R., Langdon S.P., Cameron D.A. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr. Relat. Cancer 2006, 13:1121-1133.
117. Lacroix M., LeClercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol. Cell Endocrinol. 2004, 219:1-7.
118. Lai A., Kahraman M., Govek S., Nagasawa J., Bonnefous C., Julien J., Douglas K., Sensintaffar J., Lu N., Lee K.J., Aparicio A., Kaufman J., Qian J., Shao G., Prudente R., Moon M.J., Joseph J.D., Darimont B., Brigham D., Grillot K., Heyman R., Rix P.J., Hager J.H., Smith N.D. Identification of GDC-0810 (ARN-810), an orally Bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast Cancer xenografts. J. Med. Chem. 2015, 58:4888-4904.
119. Lee A.S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 2014, 14:263-276.
120. Leygue E., Murphy L.C. A bi-faceted role of estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2013, 20:R127-R139.
121. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., He X., Liu S., Hoog J., Lu C., Ding L., Griffith O.L., Miller C., Larson D., Fulton R.S., Harrison M., Mooney T., McMichael J.F., Luo J., Tao Y., Goncalves R., Schlosberg C., Hiken J.F., Saied L., Sanchez C., Giuntoli T., Bumb C., Cooper C., Kitchens R.T., Lin A., Phommaly C., Davies S.R., Zhang J., Kavuri M.S., McEachern D., Dong Y.Y., Ma C., Pluard T., Naughton M., Bose R., Suresh R., McDowell R., Michel L., Aft R., Gillanders W., DeSchryver K., Wilson R.K., Wang S., Mills G.B., Gonzalez-Angulo A., Edwards J.R., Maher C., Perou C.M., Mardis E.R., Ellis M.J. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
122. Lippman M.E., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone responsive human breast cancer cells in long term tissue culture. Cancer Res. 1976, 36:4595-4601.
123. Loi S., Haibe-Kains B., Majjaj S., Lallemand F., Durbecq V., Larsimont D., Gonzalez-Angulo A.M., Pusztai L., Symmans W.F., Bardelli A., Ellis P., Tutt A.N., Gillett C.E., Hennessy B.T., Mills G.B., Phillips W.A., Piccart M.J., Speed T.P., McArthur G.A., Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10208-10213.
124. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 2006, 281:9607-9615.
125. Lopez-Knowles E., O'Toole S.A., McNeil C.M., Millar E.K., Qiu M.R., Crea P., Daly R.J., Musgrove E.A., Sutherland R.L. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer 2010, 126:1121-1131.
126. Mackay A., Weigelt B., Grigoriadis A., Kreike B., Natrajan R., A'Hern R., Tan D.S., Dowsett M., Ashworth A., Reis-Filho J.S. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J. Natl. Cancer Inst. 2011, 103:662-673.
127. Manavathi B., Samanthapudi V.S., Gajulapalli V.N. Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development. Front. Cell Dev. Biol. 2014, 2:34.
128. Marcom P.K., Isaacs C., Harris L., Wong Z.W., Kommarreddy A., Novielli N., Mann G., Tao Y., Ellis M.J. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 2007, 102:43-49.
129. Martelotto L.G., Ng C.K., Piscuoglio S., Weigelt B., Reis-Filho J.S. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014, 16:210.
130. Maycotte P., Gearheart C.M., Barnard R., Aryal S., Mulcahy Levy J.M., Fosmire S.P., Hansen R.J., Morgan M.J., Porter C.C., Gustafson D.L., Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014, 74:2579-2590.
131. Mayer E.L. Targeting breast cancer with CDK inhibitors. Curr. Oncol. Rep. 2015, 17:443.
132. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
133. Merenbakh-Lamin K., Ben-Baruch N., Yeheskel A., Dvir A., Soussan-Gutman L., Jeselsohn R., Yelensky R., Brown M., Miller V.A., Sarid D., Rizel S., Klein B., Rubinek T., Wolf I. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013, 73:6856-6864.
134. Miller T.W., Balko J.M., Arteaga C.L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 2011, 29:4452-4461.
135. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D'Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERalpha action in breast cancer. Nature 2015, 523:313-317.
136. Murphy L.C., Leygue E. The role of estrogen receptor-beta in breast cancer. Semin. Reprod. Med. 2012, 30:5-13.
137. Murphy L.C., Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 2006, 13:327-334.
138. Murphy L., Cherlet T., Lewis A., Banu Y., Watson P. New insights into estrogen receptor function in human breast cancer. Ann. Med. 2003, 35:614-631.
139. Murphy L.C., Skliris G.P., Rowan B.G., Al-Dhaheri M., Williams C., Penner C., Troup S., Begic S., Parisien M., Watson P.H. The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. J. Steroid Biochem. Mol. Biol. 2009, 114:90-95.
140. Murphy L.C., Seekallu S.V., Watson P.H. Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer 2011, 18:R1-14.
141. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
142. Naughton C., MacLeod K., Kuske B., Clarke R., Cameron D.A., Langdon S.P. Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. Mol. Endocrinol. 2007, 21:2615-2626.
143. Nehra R., Riggins R., Shajahan A.N., Zwart A., Crawford A.C., Clarke R. BCL2 and CASP8 regulation by NFκB differentially affect mitochondrial function and cell fate in antiestrogen senstiive and resistant breast cancer cells. FASEB J. 2010, 24:2039-2054.
144. Ning Y., Riggins R., Mulla J.E., Chung H., Zwart A., Clarke R. Interferon gamma restores breast cancer sensitivity to Fulvestrant by regulating STAT1, IRF1, NFkB, BCL2 family members and signaling to a caspase-dependent apoptosis. Mol. Cancer Ther. 2010, 9:1274-1285.
145. Novak B., Sible J.C., Tyson J.J. Checkpoints in the cell cycle. Encycl. Life Sci. 2002, 1-8.
146. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
147. Oh A., List H.J., Reiter R., Mani A., Zhang Y., Gehan E., Wellstein A., Riegel A.T. The nuclear receptor roactivator AIB1 mediates insulin-like growth gactor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 2004, 64:8299-8308.
148. Ojo D., Wei F., Liu Y., Wang E., Zhang H., Lin X., Wong N., Bane A., Tang D. Factors promoting tamoxifen resistance in breast cancer via stimulating breast cancer stem cell expansion. Curr. Med. Chem. 2015.
149. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., Wong J., Allred D.C., Clark G.M., Schiff R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 2003, 95:353-361.
150. Otto A.M., Paddenberg R., Schubert S., Mannherz H.G. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J. Cancer Res. Clin. Oncol. 1996, 122:603-612.
151. Parmar J.H., Cook K.L., Shajahan-Haq A.N., Clarke P.A., Tavassoly I., Clarke R., Tyson J.J., Baumann W.T. Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer. Interface Focus 2013, 3:20130012.
152. Pereira E.R., Frudd K., Awad W., Hendershot L.M. Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). J. Biol. Chem. 2014, 289:3352-3364.
153. Perou C.M., Sorlie T., Eisen M.B., Van de R.M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
154. Piccart M., Lohrisch C., Di L.A., Larsimont D. The predictive value of HER2 in breast cancer. Oncology 2001, 61(Suppl. 2):73-82.
155. Polyak K. Heterogeneity in breast cancer. J. Clin. Invest 2011, 121:3786-3788.
156. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., Linette G.P., Meyer N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff M.S., Minor D., Salama A.K., Taylor M., Ott P.A., Rollin L.M., Horak C., Gagnier P., Wolchok J.D., Hodi F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
157. Powell A.A., Talasaz A.H., Zhang H., Coram M.A., Reddy A., Deng G., Telli M.L., Advani R.H., Carlson R.W., Mollick J.A., Sheth S., Kurian A.W., Ford J.M., Stockdale F.E., Quake S.R., Pease R.F., Mindrinos M.N., Bhanot G., Dairkee S.H., Davis R.W., Jeffrey S.S. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012, 7:e33788.
158. Province M.A., Altman R.B., Klein T.E. Interpreting the CYP2D6 results from the international tamoxifen pharmacogenetics consortium. Clin. Pharmacol. Ther. 2014, 96:144-146.
159. Pusztai L., Mazouni C., Anderson K., Wu Y., Symmans W.F. Molecular classification of breast cancer: limitations and potential. Oncologist 2006, 11:868-877.
160. Qu Z., Van G.S., Roy A.M., Westbrook L., Nasrin M., Maxuitenko Y., Frost A.R., Carey D., Wang W., Li R., Grizzle W.E., Thottassery J.V., Kern F.G. Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors. Cancer Res. 2008, 68:6232-6240.
161. Quesnel B. Tumor dormancy and immunoescape. APMIS 2008, 116:685-694.
162. Rae J.M. CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients. Clin. Pharmacol. Ther. 2013, 94:183-185.
163. Ramanujan S., Koenig G.C., Padera T.P., Stoll B.R., Jain R.K. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res. 2000, 60:1442-1448.
164. Ratain M.J., Nakamura Y., Cox N.J. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin. Pharmacol. Ther. 2013, 94:185-187.
165. Reiter R., Wellstein A., Riegel A.T. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J. Biol. Chem. 2001, 276:39736-39741.
166. Riggins R., Zwart A., Nehra R., Agarwal P., Clarke R. The NFκB inhibitor parthenolide restores ICI 182,780 (Faslodex; Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol. Cancer Ther. 2005, 4:33-41.
167. Robertson J.F., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., Kleeberg U.R., Come S.E., Vergote I., Gertler S., Buzdar A., Webster A., Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
168. Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., Kalyana-Sundaram S., Wang R., Ning Y., Hodges L., Gursky A., Siddiqui J., Tomlins S.A., Roychowdhury S., Pienta K.J., Kim S.Y., Roberts J.S., Rae J.M., Van Poznak C.H., Hayes D.F., Chugh R., Kunju L.P., Talpaz M., Schott A.F., Chinnaiyan A.M. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45:1446-1451.
169. Rossi E., Morabito A., De M.E., Di R.F., Esposito G., Gravina A., Labonia V., Landi G., Nuzzo F., Pacilio C., Piccirillo M.C., D'Aiuto G., D'Aiuto M., Rinaldo M., Botti G., Gallo C., Perrone F. de, M. A. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. J. Clin. Oncol. 2008, 26:264-270.
170. Sabatier R., Finetti P., Mamessier E., Adelaide J., Chaffanet M., Ali H.R., Viens P., Caldas C., Birnbaum D., Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2015, 6:5449-5464.
171. Samaddar J.S., Gaddy V.T., Duplantier J., Thandavan S.P., Shah M., Smith M.J., Browning D., Rawson J., Smith S.B., Barrett J.T., Schoenlein P.V. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 2008, 7:2977-2987.
172. Schoenlein P.V., Periyasamy-Thandavan S., Samaddar J.S., Jackson W.H., Barrett J.T. Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance. Autophagy 2009, 5:400-403.
173. Schwartz-Roberts J.L., Shajahan A.N., Cook K.L., Warri A., Abu-Asab M., Clarke R. GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol. Cancer Ther. 2013, 12:448-459.
174. Scriven P., Coulson S., Haines R., Balasubramanian S., Cross S., Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br. J. Cancer 2009, 101:1692-1698.
175. Seaman W.E., Talal N. The effect of 17β-estradiol on natural killing in the mouse. Natural Cell-mediated Immunity against Tumors 1980, 765-777. Academic Press, New York. R.B. Herberman (Ed.).
176. Shajahan A.N., Riggins R., Clarke R. The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009, 22:241-246.
177. Shajahan-Haq A.N., Cook K.L., Schwartz-Roberts J.L., Eltayeb A.E., Demas D.M., Warri A.M., Facey C.O., Hilakivi-Clarke L.A., Clarke R. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol. Cancer 2014, 13:239.
178. Smith I.E., Walsh G., Skene A., Llombart A., Mayordomo J.I., Detre S., Salter J., Clark E., Magill P., Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 2007, 25:3816-3822.
179. Sonnenschein C., Soto A.M. An updated review of environmental estrogen and androgen mimics and antagonists. J. Steroid Biochem. Mol. Biol. 1998, 65:143-150.
180. Stanway S.J., Purohit A., Woo L.W., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V., Reed M.J., Coombes R.C. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 2006, 12:1585-1592.
181. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., Flockhart D.A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003, 95:1758-1764.
182. Tavassoly I., Parmar J., Shajahan-Haq A.N., Clarke R., Baumann W.T., Tyson J.J. Dynamic modeling of the interaction between autophagy and apoptosis in mammalian cells. CPT Pharmacomet. Syst. Pharmacol. 2015, 4:263-272.
183. Thompson E.W., Katz D., Shima T.B., Wakeling A.E., Lippman M.E., Dickson R.B. ICI 164,384: a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res. 1989, 49:6929-6934.
184. Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., Li Z., Gala K., Fanning S., King T.A., Hudis C., Chen D., Taran T., Hortobagyi G., Greene G., Berger M., Baselga J., Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45:1439-1445.
185. Traina T.A., Dugan U., Higgins B., Kolinsky K., Theodoulou M., Hudis C.A., Norton L. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis. 2010, 31:7-18.
186. Turnbull A.K., Arthur L.M., Renshaw L., Larionov A.A., Kay C., Dunbier A.K., Thomas J.S., Dowsett M., Sims A.H., Dixon J.M. Accurate prediction and validation of response to endocrine therapy in breast cancer. J. Clin. Oncol. 2015, 33:2270-2278.
187. Turner N.C., Reis-Filho J.S. Tackling the diversity of triple-negative breast cancer. Clin. Cancer Res. 2013, 19:6380-6388.
188. Tyson J.J., Novak B. Control of cell growth, division and death: information processing in living cells. Interface Focus 2014, 4:20130070.
189. Tyson J.J., Baumann W.T., Chen C., Verdugo A., Tavassoly I., Wang Y., Weiner L.M., Clarke R. Dynamic modeling of oestrogen signalling and cell fate in breast cancer cells. Nat. Rev. Cancer 2011, 11:523-532.
190. Uhr J.W., Pantel K. Controversies in clinical cancer dormancy. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12396-12400.
191. Urra H., Hetz C. A novel ER stress-independent function of the UPR in angiogenesis. Mol. Cell 2014, 54:542-544.
192. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 2005, 23:7212-7220.
193. van A.E., Romijn E.P., Maggioni C., Mezghrani A., Sitia R., Braakman I., Heck A.J. Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity 2003, 18:243-253.
194. Venditti M., Iwasiow B., Orr F.W., Shiu R.P. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int. J. Cancer 2002, 99:35-42.
195. Venet D., Dumont J.E., Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput. Biol. 2011, 7:e1002240.
196. Vergote I., Robertson J.F. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br. J. Cancer 2004, 90(Suppl. 1):S11-S14.
197. Wang L.H., Yang X.Y., Zhang X., An P., Kim H.J., Huang J., Clarke R., Osborne C.K., Inman J.K., Appella E., Farrar W.L. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 2006, 10:487-499.
198. Webber V.L., Dixon J.M.D. Role of endocrine therapy in ER+/HER2+ breast cancers. Breast Cancer Manag. 2014, 3:103-111.
199. Weidner N. Chapter 14. Measuring intratumoral microvessel density. Methods Enzymol. 2008, 444:305-323.
200. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010, 220:263-280.
201. Yu M., Bardia A., Aceto N., Bersani F., Madden M.W., Donaldson M.C., Desai R., Zhu H., Comaills V., Zheng Z., Wittner B.S., Stojanov P., Brachtel E., Sgroi D., Kapur R., Shioda T., Ting D.T., Ramaswamy S., Getz G., Iafrate A.J., Benes C., Toner M., Maheswaran S., Haber D.A. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345:216-220.
202. Yuhas J.M., Tarleton A.E. Dormancy and spontaneous recurrence of human breast cancer in vitro. Cancer Res. 1978, 38:3584-3589.
203. Zhang B., Li H., Riggins R., Zhan M., Xuan J., Zhang Z., Hoffman E.P., Clarke R., Wang Y. Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics 2009, 25:526-532.
204. Zhang B., Li H., Clarke R., Hilakivi-Clarke L.A., Wang Y. Differential dependency network analysis to identify topological changes in biological networks. Medical Biostatistics for Complex Diseases 2010, 185-205. Wiley-VCH Verlag GmbH & Co., Weinheim. F. Emmert-Streib, M. Dehmer (Eds.).
205. Zhang L., Gong C., Lau S.L., Yang N., Wong O.G., Cheung A.N., Tsang J.W., Chan K.Y., Khoo U.S. SpliceArray profiling of breast cancer reveals a novel variant of NCOR2/SMRT that is associated with tamoxifen resistance and control of ERalpha transcriptional activity. Cancer Res. 2013, 73:246-255.
206. Zhu Y., Singh B., Hewitt S., Liu A., Gomez B., Wang A., Clarke R. Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor alpha and progesterone receptor proteins in breast cancer tissue microarrays. Int. J. Oncol. 2006, 28:67-76.